Analyst Maury Raycroft of Jefferies maintained a Buy rating on Dianthus Therapeutics, with a price target of $51.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Maury Raycroft’s rating is based on the promising clinical data from Dianthus Therapeutics’ recent trials. The company demonstrated significant efficacy in treating generalized myasthenia gravis (gMG) with their drug claseprubart, showing a notable improvement in MG-ADL scores compared to placebo. The safety profile was also favorable, with no serious adverse events reported, which enhances confidence in the drug’s potential.
Furthermore, the results provide a positive outlook for future studies in other conditions like CIDP and MMN, with key readouts expected in the second half of 2026. The competitive profile of claseprubart, especially against existing treatments, and the potential for market growth with more self-administered options, support the Buy rating. The company’s strategic plans to engage with the FDA and explore different dosing regimens further solidify the investment potential in Dianthus Therapeutics.
According to TipRanks, Raycroft is a 4-star analyst with an average return of 9.1% and a 41.45% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Cardiff Oncology, and KalVista Pharmaceuticals.